Quick Answer
Verrica Pharmaceuticals Inc. reported Total Revenue of $35.58 million for fiscal year 2025.
Verrica Pharmaceuticals Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $35.58M +370.2% |
$7.57M +47.7% |
$5.12M -43.3% |
$9.03M -24.7% |
$12.00M | — |
| Revenue (ASC 606) | — | $7.57M +47.7% |
$5.12M -43.3% |
$9.03M -24.7% |
$12.00M | — |
| Net Income | -$17.89M +76.6% |
-$76.58M -14.3% |
-$67.00M -173.6% |
-$24.49M +30.2% |
-$35.08M +17.8% |
-$42.69M -51.4% |
| Diluted EPS | -$1.68 +88.6% |
-$14.78 -898.6% |
-$1.48 -105.6% |
-$0.72 +44.6% |
-$1.30 | — |
| Total Assets | $47.13M -12.9% |
$54.13M -33.7% |
$81.60M +82.5% |
$44.72M -44.2% |
$80.12M +8.1% |
$74.15M +8.4% |
| Cash and Equivalents | $30.15M -34.9% |
$46.33M -33.4% |
$69.55M +102.9% |
$34.27M +117.6% |
$15.75M +47.4% |
$10.69M +15.6% |
| Long-Term Debt | $0.00 -100.0% |
$30.98M -27.7% |
$42.87M | $0.00 | — | — |
| Stockholders Equity | $24.74M +350.9% |
-$9.86M -149.9% |
$19.76M -50.6% |
$40.03M +22.8% |
$32.60M -1.2% |
$32.99M -49.3% |
| R&D Expense | $8.86M -25.2% |
$11.84M +163.1% |
$4.50M -63.1% |
$12.20M -23.4% |
$15.93M +1.6% |
$15.67M +1.5% |
| Operating Income | -$12.19M +81.5% |
-$65.92M -0.2% |
-$65.76M -208.8% |
-$21.30M +31.1% |
-$30.91M +23.1% |
-$40.18M -33.6% |
| Shares Outstanding | 17.18M +87.2% |
9.18M -78.4% |
42.41M +3.2% |
41.09M +49.3% |
27.52M +8.2% |
25.44M -1.3% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $14.34M | +905.4% | +12.9% |
| Revenue (ASC 606) | June 30, 2025 | $12.70M | +145.4% | +269.4% |
| Net Income | September 30, 2025 | -$274.0K | +98.8% | -234.3% |
| Diluted EPS | September 30, 2025 | -$0.03 | +99.4% | -250.0% |
| Total Assets | September 30, 2025 | $40.90M | +24.2% | +4.6% |
| Cash and Equivalents | September 30, 2025 | $21.10M | -8.1% | +37.0% |
| Long-Term Debt | September 30, 2025 | $21.62M | -50.1% | -12.0% |
| Stockholders Equity | September 30, 2025 | -$17.04M | +50.0% | +2.5% |
| R&D Expense | September 30, 2025 | $2.21M | -8.3% | +19.4% |
| Operating Income | September 30, 2025 | $1.63M | +107.9% | +7.7% |
| Shares Outstanding | September 30, 2025 | 9.49M | -79.2% | +2.5% |
- Verrica Pharmaceuticals Inc. reported Total Revenue of $35.58 million for fiscal year 2025.
- Verrica Pharmaceuticals Inc. showed an increase of +370.2% in Total Revenue compared to the prior fiscal year.
- Verrica Pharmaceuticals Inc. reported Revenue (ASC 606) of $7.57 million for fiscal year 2024.
- Verrica Pharmaceuticals Inc. showed an increase of +47.7% in Revenue (ASC 606) compared to the prior fiscal year.
- Verrica Pharmaceuticals Inc. reported Net Income of -$17.89 million for fiscal year 2025.
- Verrica Pharmaceuticals Inc. showed an increase of +76.6% in Net Income compared to the prior fiscal year.
- Verrica Pharmaceuticals Inc. reported Diluted EPS of $1.68 per share (loss) for fiscal year 2025.
- Verrica Pharmaceuticals Inc. showed an increase of +88.6% in Diluted EPS compared to the prior fiscal year.
- Verrica Pharmaceuticals Inc. reported Total Assets of $47.13 million for fiscal year 2025.
- Verrica Pharmaceuticals Inc. showed a decrease of -12.9% in Total Assets compared to the prior fiscal year.
- Verrica Pharmaceuticals Inc. reported Cash and Equivalents of $30.15 million for fiscal year 2025.
- Verrica Pharmaceuticals Inc. showed a decrease of -34.9% in Cash and Equivalents compared to the prior fiscal year.
- Verrica Pharmaceuticals Inc. reported Long-Term Debt of $0.00 for fiscal year 2025.
- Verrica Pharmaceuticals Inc. showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
- Verrica Pharmaceuticals Inc. reported Stockholders Equity of $24.74 million for fiscal year 2025.
- Verrica Pharmaceuticals Inc. showed an increase of +350.9% in Stockholders Equity compared to the prior fiscal year.
- Verrica Pharmaceuticals Inc. reported R&D Expense of $8.86 million for fiscal year 2025.
- Verrica Pharmaceuticals Inc. showed a decrease of -25.2% in R&D Expense compared to the prior fiscal year.
- Verrica Pharmaceuticals Inc. reported Operating Income of -$12.19 million for fiscal year 2025.
- Verrica Pharmaceuticals Inc. showed an increase of +81.5% in Operating Income compared to the prior fiscal year.
- Verrica Pharmaceuticals Inc. reported Shares Outstanding of 17.18 million shares for fiscal year 2025.
- Verrica Pharmaceuticals Inc. showed an increase of +87.2% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: